Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 1/20 | 0.52 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.43 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.43 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.43 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.43 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.43 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.43 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.43 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.43 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.43 |
| ▸ | CMA1 | P23946 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4245409 | 0.98 | ALOX5 (0.51) | ALOX5PKMHDAC3HDAC4HDAC1 | |
| SCHEMBL6999400 | 0.83 | ALOX5 (0.54) | ALOX5PKMHDAC3HDAC4HDAC1 | |
| SCHEMBL12971503 | 0.83 | ALOX5 (0.50) | ALOX5PKMHDAC3HDAC4HDAC1 | |
| SCHEMBL10069422 | 0.83 | ALOX5 (0.56) | ALOX5PKMHDAC3HDAC4HDAC1 | |
| SCHEMBL8126573 | 0.81 | ALOX5 (0.57) | ALOX5PKMHDAC3HDAC4HDAC1 | |
| SCHEMBL4251872 | 0.81 | ALOX5 (0.54) | ALOX5PKMHDAC3HDAC4HDAC1 | |
| SCHEMBL5448967 | 0.81 | ALOX5 (0.48) | ALOX5PKMHDAC3HDAC4HDAC1 | |
| SCHEMBL10821183 | 0.80 | ALOX5 (0.52) | ALOX5PKMHDAC3HDAC4HDAC1 | |
| SCHEMBL8627954 | 0.80 | ALOX5 (0.52) | ALOX5PKMHDAC3HDAC4HDAC1 | |
| SCHEMBL8126570 | 0.80 | ALOX5 (0.52) | ALOX5PKMHDAC3HDAC4HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1888566-A1 | 2-[(ISOQUINOLIN-3-CARBONYL)AMINO]-PROPIONIC ACID DERIVATIVES AS INHIBITORS OF FACTORS XI AND IX FOR THE TREATMENT OF THROMBOSIS | Transtech Pharma, Inc. (US) | 2008-02-20 | — | — | EP | disclosed |
| WO-2006093823-A9 | 2- [ ISOQUINOLIN-S - CARBONYL ) AMINO] -PROPIONIC ACID DERIVATIVES AS INHIBITORS OF FACTORS XI AND IX FOR THE TREATMENT OF THROMBOSIS | TRANSTECH PHARMA INC (US) | 2006-11-02 | — | — | WO | disclosed |
| US-20060223761-A1 | Methods and compounds for inhibiting beta-amyloid peptide release and/or its synthesis | ELAN PHARMACEUTICALS, INC. (US) | 2006-10-05 | — | — | US | disclosed |
| WO-2006093823-A1 | 2- [ ISOQUINOLIN-S - CARBONYL ) AMINO] -PROPIONIC ACID DERIVATIVES AS INHIBITORS OF FACTORS XI AND IX FOR THE TREATMENT OF THROMBOSIS | TRANSTECH PHARMA, INC. (US) | 2006-09-08 | — | — | WO | disclosed |
| US-6888022-B2 | Methods and compounds for inhibiting β-amyloid peptide release and/or its synthesis | ATHENA NEUROSCIENCES, INC. (US) | 2005-05-03 | — | — | US | disclosed |
| US-6861558-B2 | Methods and compounds for inhibiting β-amyloid peptide release and/or its synthesis | ELAN PHARMACEUTICALS, INC. (US) | 2005-03-01 | — | — | US | disclosed |
| US-20030229024-A1 | Methods and compounds for inhibiting beta-amyloid peptide release and/or its synthesis | AUDIA JAMES E (US) | 2003-12-11 | — | — | US | disclosed |
| US-6476263-B1 | Compounds for inhibiting β-amyloid peptide release and/or its synthesis | ELAN PHARMACEUTICALS, INC. | 2002-11-05 | — | — | US | disclosed |
| US-20020052322-A1 | Methods and compounds for inhibiting beta-amyloid peptide release and/or its synthesis | ELAN PHARMACEUTICALS, INC. | 2002-05-02 | — | — | US | disclosed |
| US-6211235-B1 | ALZHEIMERS DISEASE | ELAN PHARMACEUTICALS, INC. | 2001-04-03 | — | — | US | disclosed |
| US-6207710-B1 | FOR THERAPY OF ALZHEIMER'S DISEASE | ELAN PHARMACEUTICALS, INC. | 2001-03-27 | — | — | US | disclosed |
| US-6191166-B1 | ALZHEIMER'S DISEASE | ELAN PHARMACEUTICALS, INC. | 2001-02-20 | — | — | US | disclosed |
| CN-1238779-A | Methods and compounds for inhibiting beta-amyloid peptide release and/or its synthesis | ELAN PHARM INC (US) | 1999-12-15 | — | — | CN | disclosed |
| EP-0942924-A2 | METHODS AND COMPOUNDS FOR INHIBITING $g(b)-AMYLOID PEPTIDE RELEASE AND/OR ITS SYNTHESIS | Elan Pharmaceuticals, Inc. (US) | 1999-09-22 | — | — | EP | disclosed |
| WO-1998022494-A9 | METHODS AND COMPOUNDS FOR INHIBITING β-AMYLOID PEPTIDE RELEASE AND/OR SYNTHESIS | — | 1998-08-20 | — | — | WO | disclosed |
| WO-1998022494-A2 | METHODS AND COMPOUNDS FOR INHIBITING β-AMYLOID PEPTIDE RELEASE AND/OR SYNTHESIS | ELAN PHARMACEUTICALS, INC. (US) | 1998-05-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020052322-A1 | Methods and compounds for inhibiting beta-amyloid peptide release and/or its synthesis | APP, BACE1, IAPP | ALOX5 1016/4885PKM 3084/4885HDAC3 4055/4885 |
| US-20060223761-A1 | Methods and compounds for inhibiting beta-amyloid peptide release and/or its synthesis | APP, BACE1, IAPP | ALOX5 1062/4885PKM 2945/4885HDAC3 3952/4885 |
| US-20030229024-A1 | Methods and compounds for inhibiting beta-amyloid peptide release and/or its synthesis | APP, BACE1, IAPP | ALOX5 1016/4885PKM 3084/4885HDAC3 4055/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.